Cipla launches leuprolide acetate injection depot 22.5 mg in US
Cipla Limited and its wholly owned subsidiary Cipla USA Inc., has announced the launch of leuprolide acetate injection depot 22.5mg.
The product was approved by the United States Food and Drug Administration (FDA) based on a New Drug Application (NDA) submitted under the 505(b)(2) regulatory pathway.
Leuprolide acetate injection depot contains 22.5 mg of leuprolide acetate for 3-month administration given as a single dose injection. It is supplied as lyophilized microspheres in a single dose vial as a kit with a prefilled syringe containing 2ml 0.8% mannitol solution and an easy-to-use Mixject transfer device for a single dose injection. It is indicated for palliative treatment of advanced prostate cancer.
Arunesh Verma, CEO
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!